ShareThis Page

Boston-based startup to test wastewater for drug, opioid use

Renatta Signorini
| Tuesday, March 13, 2018, 8:00 a.m.
OxyContin, an opioid painkiller.
OxyContin, an opioid painkiller.

A Boston-based startup company that is focused on extracting opioid consumption data from sewage won $10,000 on Sunday during a mayors' conference.

Biobot Analytics won the money after a pitch competition judged by mayors from around the country at the South by Southwest Conference in Austin, reported Cities can use Biobot's technology to examine wastewater to estimate levels of drug use in specific areas, according to a company profile by Boston Magazine .

"We are creating a new layer of human health data intelligence in our cities and, to start, we're focusing on the biggest public health crisis in the United States," said Newsha Ghaeli, co-founder and president, during her pitch.In addition to the money, Biobot Analytics won the opportunity to present during the U.S. Conference of Mayors annual meeting.

'We measure the concentration of opioids and other drugs in sewage in order to estimate consumption in neighborhoods," Ghaeli said during the pitch.

Cambridge, Mass. and Cary, N.C. have agreed to use the technology, both and Boston Magazine reported. Between 2000 and 2016, 600,000 people across the country have died from a drug overdose, according to the Centers for Disease Control and Prevention. Opioids, such as prescription pain pills and heroin, are driving the epidemic.

Renatta Signorini is a Tribune-Review staff writer. Reach her at 724-837-5374, or via Twitter @byrenatta.

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.

click me